Do albuminuria and ADMA reflect kidney vascular injury and endothelial dysfunction?

Albuminuria and asymmetric dimethylarginine (ADMA) both relate to vascular biology, but their evidentiary roles differ: albuminuria is an indirect clinical marker of kidney damage and cardiorenal risk, whereas ADMA’s inhibition of nitric-oxide synthase (NOS) is a well-established molecular mechanism.

Albuminuria and renal vascular injury

• Albuminuria is a plausible indicator of renal microvascular and glomerular endothelial injury. Injury to the glomerular endothelial glycocalyx can increase albumin permeability; experimental disruption of this layer increases albumin leakage.
• It is not specific for endothelial or microvascular damage. Albumin excretion also depends on podocyte/filtration-barrier abnormalities and tubular albumin handling.
• Clinically, urinary albumin-to-creatinine ratio (ACR) is a marker of kidney damage, not a standalone endothelial-function test. ACR ≥30 mg/g is abnormal; chronicity requires persistence for ≥3 months, with an elevated random sample confirmed using a first-morning specimen.

ADMA–NOS–endothelial pathway

• ADMA is an endogenous, reversible competitive NOS inhibitor, competing with L-arginine at the active site—particularly for endothelial NOS (eNOS)—and reducing nitric-oxide (NO) generation. Reported kinetic estimates include a Ki around 0.9 μM and assay-dependent IC50 values of 2–10 μM.
• Reduced NO bioavailability provides a strong mechanism for impaired endothelium-dependent vasodilation. At higher concentrations, ADMA may also promote NOS uncoupling, decreasing NO and increasing superoxide.
• DDAH metabolizes most ADMA to citrulline and dimethylamine, making DDAH activity a biologically relevant determinant of ADMA exposure and endothelial NO signaling.

Human relevance

• In a study of 201 people with CKD and 201 controls, higher ADMA in CKD and lower flow-mediated dilation with more severe CKD were inversely correlated. Experimental ADMA elevation in volunteers impaired forearm flow-mediated dilation and increased blood pressure.
• These findings support vascular relevance, although human evidence does not establish that lowering ADMA reliably restores endothelial function or clinical outcomes.

Bottom line

• Albuminuria can indirectly reflect renal endothelial/microvascular injury but remains nonspecific; ADMA-mediated NOS inhibition and reduced NO bioavailability are strongly supported mechanisms that can contribute to endothelial dysfunction.